Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
REGN
Regeneron Pharma
$600.00
Login to see Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Technical Indicators
MACD above signal line
Chart
$556.53 (+7.81%)
$570.59 (+5.15%)
$571.67 (+4.96%)
$990.68 (-39.44%)
REGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
REGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
REGN Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayREGN Earnings
The TTM reflects 12-month period, providing review of REGN financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
NVS
132.39
+1.08%
SNY
50.90
+1.52%
MRK
89.19
-0.36%
AZN
85.31
+1.98%
ABBV
233.87
-1.12%
What is REGN current stock price?
What are REGN stock strengths?
What risks are associated with REGN stock?
When is REGN next earnings report?
What is REGN market cap and volume?
What is REGN's current Stock IQ?
Should I buy REGN stock right now?
Is REGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for REGN?
What does a 'Strong Sell' rating mean for REGN?
What factors influence REGN's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
REGN
Regeneron Pharma
Current Price
$600.00
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Technical Indicators
MACD above signal line
Linked to REGN
NVS
132.39
+1.08%
SNY
50.90
+1.52%
MRK
89.19
-0.36%
AZN
85.31
+1.98%
ABBV
233.87
-1.12%
Login to unlock Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$556.53 (+7.81%)
$570.59 (+5.15%)
$571.67 (+4.96%)
$990.68 (-39.44%)
REGN Analysts Opinion
REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
REGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
REGN Street view is extremely bullish and have positive views on the near-term outlook
REGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayREGN Earnings
The TTM data reflects the most recent 12-month period, providing overview of REGN financial performance.
REGN Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
REGN Latest Analysis
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17 Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE trial which demonstrated that semaglutide and trevogrumab together preserved lean muscle mass while treating obesity with weight loss. According to the 26-week trial semaglutide by itself resulted in [….]
Thu Oct 2, 2025
Regeneron Pharmaceuticals Inc. (REGN) Draws Attention With Rare Disease Breakthrough. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) through the purchase of 12000 shares of the companys stock. According to a recent disclosure with the SEC the firms investment [….]
Thu Oct 2, 2025
Formycon Reaches Settlement With Regeneron Over United States Eylea Biosimilar Patent Disputes . (RTTNews) - Formycon AG (FYB.DE) in collaboration with its license partners Klinge Biopharma GmbH and Valorum Biologics has reached a settlement and entered into a license agreement with Regeneron Pharmaceuticals Inc. (REGN). The agreement resolves all outstanding patent disput
Thu Oct 2, 2025
Formycon stock surges after settlement with Regeneron on Eylea biosimilar.
Thu Oct 2, 2025
REGN Makes ish Cross Above Critical Moving Average. In trading on Wednesday shares of Regeneron Pharmaceuticals Inc. (Symbol: REGN) crossed above their 200 day moving average of $610.84 changing hands as high as $611.39 per share. Regeneron Pharmaceuticals Inc. shares are currently trading up about 7.8% on the day. The char
Wed Oct 1, 2025
Regenerons Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds. On September 26 Evkeeza (evinacumab-dgnb) an ANGPTL3 antibody developed by Regeneron Pharmaceuticals received an extended indication approval from the US FDA for the treatment of children from age 1 to less than 5 years old with homozygous familial [….]
Wed Oct 1, 2025
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28 2025. TARRYTOWN N.Y. Sept. 30 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: Participants may access the conference call live via webcast on the '.Investors and Media'. page of Regeneron'.s website at . To participate via telephone please register in advance at this . Upon registration all telephone participants will receive a confirmation email
Tue Sep 30, 2025
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Mon Sep 29, 2025
Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva a rare genetic condition in which muscles tendons and ligaments gradually convert [….
Mon Sep 29, 2025
FDA Approves Label Extension of REGNs Cholesterol Drug Evkeeza . Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Mon Sep 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
REGN Stock trends
REGN Stock performance
REGN Stock analysis
REGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings